About the Anti-Coagulant Drugs Market
Anticoagulants have been used for over 80 years to treat clotting disorders. It is used as a first line of defense for disorders such as deep vein thrombosis (DVT), pulmonary embolism, AF, and acute coronary syndrome. With the advent of time, traditional therapies are replaced by novel oral anticoagulants, which have better safety and efficacy profiles.
The 1990s saw rapid development in the field of direct thrombin inhibitors. Though these drugs, such as hirudin, have been in use from the early 19th century, they were accepted with the development of genetic engineering technology. The recombinant forms, such as desirudin, are also available in the market. During the same period, the focus shifted toward the development of factor Xa inhibitors, and by early 2000s, the first indirect factor Xa inhibitor, fondaparinux, was released into the market. These drugs were administered by parenteral route.
Technavio’s analysts forecast the anti-coagulants market in the US to grow at a CAGR of 6.67% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the anti-coagulants market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.
Technavio's report, Anti-Coagulants Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Johnson & Johnson
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Sanofi
• Daiichi Sankyo
Other prominent vendors
• Armatheon Inc.
• Aspen
• AstraZeneca
• Bayer
• Cellceutix
• Cosmo Pharmaceuticals SA
• CSL Behring, Eisai, GSK
• Marathon Pharmaceuticals LLC
• Ockham Biotech
• Perosphere
• Portola Pharmaceuticals
• Sagent Pharmaceuticals Inc.
• The Medicines Company
• Urigen Pharmaceuticals Inc.
• Valeant Pharmaceuticals
Market driver
• Growing prevalence of coagulation disorders
• For a full, detailed list, view our report
Market challenge
• Side-effects associated with drugs
• For a full, detailed list, view our report
Market trend
• Expected exploitation of new therapeutic use
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Anticoagulants: An overview
• Coagulation of blood
• Mechanism of action (MOA) of anticoagulants
PART 06: Reimbursement scenario
• US healthcare reform
• Reimbursement for prothrombin time/international normalized ratio (PT/INR) tests
PART 07: Anticoagulant reversal agents
PART 08: Approved anticoagulants in US
PART 09: Anticoagulants pipeline portfolio
• Rivaroxaban
• Tecarfarin
• Betrixaban (LY517717)
• ISIS-FXI antisense
• LMW Heparin MMX
• URG101
• Heparin
• FXI antibody
• FXI inhibitor
• Heparin plus DNAse
• Heparin plus other inhaled drug
PART 10: Market landscape
• Global anticoagulants market
• Anticoagulants market in US
• Five forces analysis
PART 11: Market segmentation by ROA
• Oral anticoagulants
• Injectable anticoagulants
PART 12: Market segmentation by drug class
• Factor Xa inhibitors
• Direct thrombin inhibitors
• Heparin
• Vitamin K antagonists
PART 13: Market segmentation by application
• DVT
• PE
• Acute coronary syndrome
• AF
• Hemodialysis
• Coronary angioplasty
• Surgeries
PART 14: Market drivers
• Growing prevalence of coagulation disorders
• Increase in number of surgical procedures
• Increased acceptance of NOACs
PART 15: Impact of drivers
PART 16: Market challenges
• Extensive use of generic products
• Side-effects associated with drugs
• High cost of NOACs
• Unmet needs for anticoagulant reversal agents
PART 17: Impact of drivers and challenges
PART 18: Market trends
• Expected exploitation of new therapeutic use
• Patient assistance programs
• Declining shares of heparin market
PART 19: Vendor landscape
• Competitive scenario
• Market analysis 2015
• Key vendors of anticoagulants market in US
• Johnson & Johnson
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Sanofi
• Upcoming vendors in anticoagulants market in US
• Daiichi Sankyo
• Other prominent vendors
PART 20: Appendix
• List of abbreviations
PART 21: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Timeline for development of anticoagulants
Exhibit 03: Process of blood coagulation
Exhibit 04: Mechanism of blood coagulation
Exhibit 05: Comparison of US healthcare system before and after reforms
Exhibit 06: Major anticoagulant reversal agents commonly used in market
Exhibit 07: Reversal agents approved by FDA for new oral anticoagulants
Exhibit 08: Pipeline portfolio: Anticoagulant reversal agents
Exhibit 09: Approved anticoagulants in US
Exhibit 10: Pipeline portfolio: Anticoagulant drugs
Exhibit 11: Global anticoagulants market 2015-2020 ($ billions)
Exhibit 12: Percentage share of US anticoagulants market in global market
Exhibit 13: Anticoagulants market in US 2015-2020 ($ billions)
Exhibit 14: Five forces analysis
Exhibit 15: Segmentation of anticoagulants market in US based on ROA
Exhibit 16: Market segmentation of anticoagulants market in US based on ROA 2015
Exhibit 17: Comparison of US anticoagulants market with global anticoagulants market 2015
Exhibit 18: Percentage of population treated by NOACs based on disease type in US 2015
Exhibit 19: Factors determining use of NOACs (based on their importance)
Exhibit 20: Percentage of individuals with AF treated by anticoagulants in US 2015
Exhibit 21: Percentage of individuals with DVT/PE treated by anticoagulants in US 2015
Exhibit 22: Classes of oral anticoagulants based on revenue 2015
Exhibit 23: Oral anticoagulants market in US 2015-2020 ($ billions)
Exhibit 24: Classes of injectable anticoagulants based on revenue 2015
Exhibit 25: Injectable anticoagulants market in the US 2015-2020 ($ billions)
Exhibit 26: Anticoagulants market in US by ROA 2015-2020
Exhibit 27: Anticoagulants market in US: YoY growth and revenue based on ROA 2015-2020
Exhibit 28: Segmentation of anticoagulants market in US based on drug class
Exhibit 29: Segmentation of anticoagulants market in US based on drug class 2015
Exhibit 30: Anticoagulants market in US in global anticoagulant drugs market 2015
Exhibit 31: Segmentation of factor Xa inhibitors in US 2015
Exhibit 32: Approval of factor Xa inhibitor drugs in US
Exhibit 33: Factor Xa inhibitor drugs market in US 2015-2020 ($ billions)
Exhibit 34: Some direct thrombin inhibitor drugs approved in US
Exhibit 35: Direct thrombin inhibitors market segmentation by ROA 2015
Exhibit 36: Direct thrombin inhibitor drugs market in US 2015-2020 ($ billions)
Exhibit 37: Segmentation of global heparin market by product type 2015
Exhibit 38: Global heparin market 2015-2020 ($ billions)
Exhibit 39: Heparin market in US 2015-2020 ($ billions)
Exhibit 40: Vitamin K antagonists market in US 2015-2020 ($ millions)
Exhibit 41: Anticoagulants market in US by drug class 2015-2020
Exhibit 42: Anticoagulants market in US: YoY growth and revenue based on drug class 2015-2020
Exhibit 43: Expected growth of older population in US 2010-2050
Exhibit 44: Impact of drivers
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Share of the major anticoagulant drugs in US 2013-2015 ($ billions)
Exhibit 47: Johnson & Johnson: YoY revenue and growth rate of Xarelto in US 2013-2015 ($ millions)
Exhibit 48: Johnson & Johnson: Key takeaways
Exhibit 49: BMS: YoY revenue and growth rate of Eliquis in US 2013-2015 ($ millions)
Exhibit 50: BMS: Key takeaways
Exhibit 51: Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (global) 2013-2015 ($ billions)
Exhibit 52: Boehringer Ingelheim: Key takeaways
Exhibit 53: Sanofi: YoY revenue and growth rate of Lovenox in US 2013-2015 ($ millions)
Exhibit 54: Geographical segmentation of Lovenox 2015
Exhibit 55: Sanofi: Key takeaways
Exhibit 56: Key takeaways
